ProfileJobs

Dynavax Technologies Corporation

Healthbiotechdrug developmentpharma

Dynavax Technologies Corporation is a clinical-stage biopharmaceutical company with multiple product candidates in development for the prevention of infectious disease, the treatment of autoimmune and inflammatory diseases, and the treatment of cancer. The Company develops immunotherapies based on cutting-edge Toll-Like Receptor biology and its ability to modulate the immune system.

Dynavax Technologies Corporation's clinical-stage product candidates include HBsAg-1018 is an adult hepatitis B vaccine in Phase 3 development that utilizes a proprietary TLR9 agonist to elicit a focused immune response designed to provide protection against hepatitis B; and the Company's lead cancer immunotherapy compound, SD-101, is a TLR9 agonist designed specifically for cancer and capable of maximal type 1 IFN induction and efficient maturation of plasmacytoid dendritic cells to antigen-presenting cells. 

Revenue(Q1, 2017)
$148 K
Market capitalization(2017-09-19)
$1 B
Company Growth (employees)
Type
Public
HQ
Berkeley, US
Founded
1996
Size (employees)
251 (est)
Website
dynavax.com
Dynavax Technologies Corporation was founded in 1996 and is headquartered in Berkeley, US

Dynavax Technologies Corporation Office Locations

Dynavax Technologies Corporation has an office in Berkeley
Berkeley, US (HQ)
100 2929 Seventh Street

Dynavax Technologies Corporation Data and Metrics

Dynavax Technologies Corporation Financial Metrics

Dynavax Technologies Corporation's revenue was reported to be $148 k in Q1, 2017
USD

Revenue (Q1, 2017)

148 k

Net income (Q1, 2017)

(25.3 m)

EBIT (Q1, 2017)

(25.5 m)

Market capitalization (19-Sep-2017)

1 b

Cash (31-Mar-2017)

21.5 m
Dynavax Technologies Corporation's current market capitalization is $1 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

11.3 m11 m4.1 m11 m

Revenue growth, %

(2%)(63%)173%

R&D expense

50.9 m84.6 m86.9 m84.5 m

General and administrative expense

25.9 m17.4 m22.2 m37.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

3 m2.2 m627 k1.6 m1.2 m942 k2.6 m162 k148 k

R&D expense

23.6 m28.1 m22.2 m19.7 m24.1 m20.1 m22.8 m23.2 m16.3 m

General and administrative expense

4.1 m4.1 m4.9 m5.1 m5.5 m8.2 m9.2 m11.8 m6.5 m

Operating expense total

27.7 m32.2 m27.1 m24.8 m29.6 m28.2 m31.9 m35 m22.8 m
show all
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

23.1 m49.5 m44.8 m24.3 m

Accounts Receivable

1.6 m727 k1.4 m

Inventories

1.4 m4.1 m2.4 m6.8 m

Current Assets

192.4 m127.4 m199.9 m89.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

17 m19.7 m14.7 m36.5 m103 m38.9 m24.8 m23 m21.5 m

Accounts Receivable

1.3 m727 k909 k657 k1.2 m1.2 m

Current Assets

160.6 m134.9 m102 m97.9 m224.3 m170.7 m147.1 m117.5 m89.7 m

PP&E

8.8 m8.1 m7.5 m8.9 m11.6 m15.9 m17.4 m18.7 m16.6 m
show all
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(66.7 m)(90.7 m)(106.8 m)(112.4 m)

Depreciation and Amortization

1.3 m1.4 m1.4 m2.3 m

Accounts Receivable

(622 k)900 k(667 k)52 k

Inventories

677 k(2.7 m)1.6 m560 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(24.8 m)(29.8 m)(26.2 m)(23.6 m)(30.1 m)(27 m)(29 m)(34.7 m)(25.3 m)

Accounts Receivable

1.3 m727 k909 k657 k1.2 m1.2 m

Accounts Payable

1.9 m5 m3.3 m2.3 m2.4 m3.5 m4.5 m3.8 m1.5 m
show all
USDY, 2017

Revenue/Employee

589.6

Financial Leverage

1.1 x
Show all financial metrics

Dynavax Technologies Corporation Operating Metrics

FY, 2016

Phase III Trials

1

Phase II Trials

3

Phase I Trials

2

Phase Preclinical

2
Show all operating metrics

Dynavax Technologies Corporation Market Value History

Dynavax Technologies Corporation Revenue Breakdown

Market Position of Dynavax Technologies Corporation

Competitors

Biogen
Health - Public
Athersys
Health - Public
Ironwood Pharmaceuticals
Health - Public
Alimera Sciences
Health - Public
Compare competitors

Traffic Overview of Dynavax Technologies Corporation

Dynavax Technologies Corporation Company Life and Culture

You may also be interested in